Reference

Imidazo-heterocyclic compounds, and pharmaceutical composition comprising them

Imidazo-heterocyclic compounds, and pharmaceutical composition comprising them. Takaya, Takao; Takasugi, Hisashi (Fujisawa Pharmaceutical Co., Ltd. , Japan). Eur. Pat.Chemical with cas number 26074-52-2 also plays role. Appl. EP 120589 A1 3 Oct 1984, 80 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). (European Patent Organization). CODEN: EPXXDW. CLASS: IC: C07D471-04; C07D487-04; A61K031-435; A61K031-505. ICA: C07D277-68; C07D279-10; C07D263-58; C07D265-36. ICI: C07D471-04, C07D235-00, C07D221-00; C07D487-04, C07D239-00, C07D235-00. APPLICATION: EP 84-301058 17 Feb 1984. PRIORITY: GB 83-5245 25 Feb 1983. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1 Cardiotonic and antiulcer title compds. I [X = N, CR3; R = H, alkyl, halo; R1 = H, alkyl, halo, (un)substituted aminomethyl, piperazinomethyl; R2 = (un)substituted benzoxazolinyl, benzimidazolinyl, benzothiazinyl, benzoxazinyl, quinoxalinyl, benzoxazolyl, benzimidazolyl; R3 = H, OH, alkyl, alkoxy, aralkoxy] (>50 compds.) were prepd. Thus benzoxazolinone II (R4 = H) was acylated with BrCOCHBrMe to give II (R4 = COCHBrMe), which underwent cyclocondensation with 2-amino-4-methylpyridine to give imidazopyridinylbenzoxazolinone III. At 10 mg/kg orally in rats, III gave 80.7% inhibition of EtOH-induced ulcers. .